Cardiovascular Business January 17, 2025
Dave Fornell

Cardiology has approximately 160 of the 1,000 U.S. Food and Drug Administration (FDA)-cleared clinical artificial intelligence (AI) algorithms, ranking it No. 2 among healthcare specialties behind radiology. This ongoing trend was a major topic at the FDA Town Hall sessions during the
Transcatheter Cardiovascular Therapeutics (TCT) 2024 meeting

“The FDA is super excited and thrilled about the number of device manufacturers that are using AI to enable their devices, and the fact that a number of those devices are starting to achieve market authorization,” Stephen Browning, the agency’s assistant director for hemodynamics and heart failure diagnostics, told Cardiovascular Business.

Browning spoke in the FDA Town Hall sessions about the agency’s evolving perspectives and regulatory strategies for AI-enabled cardiovascular devices. His...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Physician, Provider, Technology
Related Articles:
Opinion: STAT+: How the FDA and CMS worked together on a new approach to paying for digital mental health treatments
FDA Nod Paves Way for AstraZeneca Drug to Become New Standard of Care in Rare Blood Cancer
FDA's health kick: New food labels, banned food dyes, and more
FDA Releases Draft Guidance on Evaluating the Risk and Credibility of AI Used in Establishing Drug and Device Safety, Effectiveness, and Quality
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson

Share This Article